tbuckley/cabot-search huggingface dataset:
Large ongoing Q fever outbreak in the south of The Netherlands, 2008
Authors: B Schimmer, G Morroy, F Dijkstra, P M Schneeberger, G Weers-Pothoff, A Timen, C Wijkmans, W van der Hoek
Journal: Eurosurveillance (2008)

Q fever is a worldwide zoonosis caused by the bacterium Coxiella burnetii which is common in a wide range of wild and domestic animals. Cattle and small ruminants, in particular sheep and goats, have been associated with large human outbreaks. Humans become infected primarily by inhaling aerosols that are contaminated by C. burnetii. Most infections remain asymptomatic but in about 40% lead to a febrile disease, pneumonia and/or hepatitis. Chronic infections, mainly endocarditis, are observed in 3 to 5% of cases, with an increased risk for pregnant women and persons with heart valve disorders or impaired immunity. Q fever in pregnancy, whether symptomatic or asymptomatic, may also result in adverse pregnancy outcomes [1]. Q fever in humans is a notifiable disease in The Netherlands. The notification criteria for a confirmed case of acute Q fever are clinical symptoms consistent with Q fever and a positive serology defined by immunofluoresence assay (IFA) test or a C. burnetii complement fixation test [2]. Also clinical patients diagnosed by PCR are considered as confirmed cases. Between 1997 and 2006, Q fever was notified rarely with an average of 11 (range 5-16) cases annually [3]. In 2007, we reported in this journal the first community outbreak of Q fever in the south of The Netherlands [4].
PROPHYLAXIS IN INFECTIOUS DISEASES.
Authors: A AHRENS
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Methylphenidate (MP) and nursing telephone intervention (NTI) for cancer-related fatigue (CRF) in advanced cancer patients: A double-blind randomized phase II trial.
Authors: Eduardo Bruera, Sriram Yennurajalingam, Pedro Emilio Perez-Cruz, David Hui, Susan Frisbee-Hume, Julio Allo, J. Lynn Palmer
Journal: Journal of Clinical Oncology (2012)

9023 Background: CRF is the most common and distressing symptom in advanced cancer patients. Preliminary studies support MP and NTI for CRF (Bruera et al. JCO 2006). The primary objective of our study was to determine the effect of MP as compared to placebo (P). A secondary objective was to investigate the role of NTI as compared to control telephone intervention (CTI). Methods: Advanced cancer patients with fatigue ≥4/10 on the Edmonton Symptom Assessment Scale (ESAS), normal cognition, no evidence of major depression and hemoglobin ≥8 were eligible. Patients were randomized to 4 groups in a 2x2 factorial design (MP+NTI, P+NTI, MP+CTI and P+CTI). Primary endpoint was Functional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale scores between day 15 and baseline. The dose and duration of methylphenidate was 5 mg every two hours, as needed, up to 20 mg/day. We tested the median difference in FACIT-F subscale scores between the groups using the Kruskal Wallis test and Wilcoxon signed rank test. Longitudinal regression analysis was conducted with a mixed model. Results: Total accrual was 197. Mean (SD) age was 58 (12), female 67% (N=148), white 72% (N=136), gastrointestinal cancers were the most common 22% (N=41). Baseline FACIT-F subscores were similar among the 4 groups. The median FACIT-F subscores showed significant improvement between Day 15 and baseline for all four groups except for P+CTI (Table): MP+NTI (4.5, P=0.004), P+NTI (8, P&lt;0.001), MP+CTI (7, P&lt;0.001), and P+CTI (5, P=0.06), with no statistically significant difference between MP and P (6 vs. 6, P=0.89). Longitudinal regression analysis showed a time effect (P&lt;0.001) and group differences for NTI vs. CTI with FACIT-F (P=0.13) and ESAS (P=0.03). Grade 3 toxicities were similar between the MP and P arms (34/93 vs. 24/97, P=0.09). Conclusions: MP was not effective as compared to P for CRF in advanced cancer patients. NTI may be effective and should be further studied. [Table: see text]
Mutations Of Genes Regulating DNA Methylation Are Common In MLL Partial Tandem Duplication AML and DNMT3A Mutations Are Associated With Adverse Outcome
Authors: Hsiao-Wen Kao, Lee-Yung Shih, Ming-Chung Kuo, Tung-Liang Lin, Sung-Tzu Liang, Chao-Ping Yang, Yu-Shu Shih, Yu-Hui Huang, Tung-Huei Lin, Der-Cherng Liang
Journal: Blood (2013)
In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy
Authors: Sourav R Choudhury, Zachary Fitzpatrick, Anne F Harris, Stacy A Maitland, Jennifer S Ferreira, Yuanfan Zhang, Shan Ma, Rohit B Sharma, Heather L Gray-Edwards, Jacob A Johnson, Aime K Johnson, Laura C Alonso, Claudio Punzo, Kathryn R Wagner, Casey A Maguire, Robert M Kotin, Douglas R Martin, Miguel Sena-Esteves
Journal: Molecular Therapy (2016)

Adeno-associated viral (AAV) vectors have shown promise as a platform for gene therapy of neurological disorders. Achieving global gene delivery to the central nervous system (CNS) is key for development of effective therapies for many of these diseases. Here we report the isolation of a novel CNS tropic AAV capsid, AAV-B1, after a single round of in vivo selection from an AAV capsid library. Systemic injection of AAV-B1 vector in adult mice and cat resulted in widespread gene transfer throughout the CNS with transduction of multiple neuronal subpopulations. In addition, AAV-B1 transduces muscle, β-cells, pulmonary alveoli, and retinal vasculature at high efficiency. This vector is more efficient than AAV9 for gene delivery to mouse brain, spinal cord, muscle, pancreas, and lung. Together with reduced sensitivity to neutralization by antibodies in pooled human sera, the broad transduction profile of AAV-B1 represents an important improvement over AAV9 for CNS gene therapy. Adeno-associated viral (AAV) vectors have shown promise as a platform for gene therapy of neurological disorders. Achieving global gene delivery to the central nervous system (CNS) is key for development of effective therapies for many of these diseases. Here we report the isolation of a novel CNS tropic AAV capsid, AAV-B1, after a single round of in vivo selection from an AAV capsid library. Systemic injection of AAV-B1 vector in adult mice and cat resulted in widespread gene transfer throughout the CNS with transduction of multiple neuronal subpopulations. In addition, AAV-B1 transduces muscle, β-cells, pulmonary alveoli, and retinal vasculature at high efficiency. This vector is more efficient than AAV9 for gene delivery to mouse brain, spinal cord, muscle, pancreas, and lung. Together with reduced sensitivity to neutralization by antibodies in pooled human sera, the broad transduction profile of AAV-B1 represents an important improvement over AAV9 for CNS gene therapy.
Abstract 16718: Energy Induced Vasodilation in a Model of Endothelial Dysfunction Requires Nitric Oxide
Authors: Brian Lindemer, Dorothee Weihrauch, Agnes Keszler, Nicole Lohr
Journal: Circulation (2015)

Introduction: Over 8 million Americans are treated for peripheral artery disease (PAD), i.e. intermittent claudication, impaired wound healing, and critical limb ischemia. Endothelial dysfunction of the microcirculation is a potential mechanism for the pathogenesis of PAD because risk factors for PAD- age, hypertension, atherosclerosis, diabetes mellitus, and active tobacco use, have been directly related to a reduction in NOS expression and NO production. These reductions in NO bioavailability impair flow mediated dilation of the brachial artery and acetylcholine induced vasodilation. We have shown energy (670 nm (R/NIR)) can increase NO independent of NOS through release of NO from nitrosyl-heme stores. We hypothesized R/NIR can stimulate vasodilation, and serve as a potential therapy to recover vasodilation in a model of endothelial dysfunction (db/db mice). Methods: Human dermal microvascular endothelial cells (HMVEC) loaded with DAF-2 were stimulated with R/NIR 100mW/cm2 up to 6J. NO was measured using HPLC of DAF-2T. To test vasodilation, facial arteries from C57Bl/6 and db/db mice were isolated, pressurized to 60mmHg, and pre-constricted with U46619. The vessels were irradiated with 670 nm light (10mW/cm2) for 5 min with 10 min dark period between irradiation. Results: HMVEC stimulated with R/NIR increased NO 28.3% (±11.2, p&lt;0.05). The NO scavenger c-PTIO inhibited R/NIR (17.0%±5.9, p&lt;0.05) but was unchanged by pre-incubation with NOS inhibitor L-NAME (1mM) (13.1% ± 5.6). Vessel diameter increased up to 17.8% (±3, p&lt;0.05) after 5 min with R/NIR. L-NAME did not affect dilation (13.74% ±2.2), however c-PTIO (100μM) could attenuate dilation (-.51% ± 1.1, p&lt;0.001). R/NIR vasodilation was abolished with vessel denudation (1.2%± 2.21, p&lt;0.001), suggesting R/NIR dilation was endothelial dependent. Impaired dilation in db/db mice was reversed, as R/NIR could significantly dilate db/db vessels after 5 min [(13.7% ± 2.8) vs. control (17.8% ±3)]. Conclusion: R/NIR vasodilation requires intact endothelium and NO, but does not require NOS. In an obesity model of endothelial dysfunction, R/NIR can significantly restore vasodilation. Therefore, R/NIR as a source for therapeutic NO should be strongly considered in the treatment of ischemic wounds.
Sport, exercise and the menstrual cycle: where is the research?
Authors: G Bruinvels, R J Burden, A J McGregor, K E Ackerman, M Dooley, T Richards, C Pedlar
Journal: British Journal of Sports Medicine (2016)

Despite a decreasing gender gap in exercise participation, there still remains a significant under-representation of women included in sport and exercise medicine research studies.1 A review of 1382 sport and exercise research studies involving over 6 million participants, from 2011 to 2013, found the representation of women to be 39%.1 The complexities of the menstrual cycle are considered major barriers to the inclusion of women in clinical trials.

Historically, partially due to concerns of potentially damaging unborn fetuses, medical trials—including drug trials—were conducted solely in men. Further, women were perceived …
Case 15-1978
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Richard H. Meade, Karl H. Proppe
Journal: New England Journal of Medicine (1978)

Presentation of CaseA 59-year-old woman was admitted to the hospital because of a sore throat and fever.She was well until one month earlier, when she began to experience increased fatigue. Three days before admission a left-sided sore throat developed, with malaise, discomfort in the left side of the neck, dysphagia and odynophagia; she observed that the pain was more severe when she opened her jaw or swallowed. On the day of admission all the symptoms were worse, and the temperature rose to 38.6°C. She was seen in the clinic, where penicillin G was prescribed. Despite one dose of . . .
PWE-136 The non-invasive detection of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: a pilot study
Authors: J Covington, M Mcfarlane, E Daulton, E Westenbrink, N O'Connell, S Wurie, C Nwokolo, KD Bardhan, R Savage, R Arasaradnam
Journal: Gut (2015)

<h3>Introduction</h3> Non Alcoholic Fatty Liver Disease (NAFLD) is the commonest cause of chronic liver disease in the western world. Current diagnostic methods, including that of the Fibroscan, have limitations, thus there is a clinical need for more robust, non-invasive screening tools. The gut microbiome is altered in several gastrointestinal and hepatic disorders resulting in altered, unique gut fermentation patterns. These patterns are detectable by analysis of volatile organic compounds (VOCs) in urine, breath and faeces. We aimed to determine if progressive fatty liver disease produced an altered VOC pattern in urine; specifically NAFLD and Non-Alcoholic Steatohepatitis (NASH). <h3>Method</h3> 34 patients were recruited; 8 NASH cirrhotics (NASH-C); 7 non-cirrhotic NASH; 4 NAFLD and 15 controls. Urine was collected and stored frozen. For assay, the samples were defrosted and aliquoted into vials, which were heated to 40 ± 0.1°C and the headspace analysed by FAIMS (Field Asymmetric Ion Mobility Spectroscopy). A previously used data processing pipeline employing a ‘Random Forrest’ classification algorithm and a 10 fold cross validation method was applied. <h3>Results</h3> Urinary VOCs could distinguish liver disease patients from controls with a sensitivity of 0.58 (0.33–0.88) but specificity of 0.93 (0.68 – 1.00); Area Under Curve (AUC) 0.73 (0.55 – 0.90). NASH/NASH-C was similarly separated from the NAFLD/control patients with a sensitivity of 0.73 (0.45–0.92), a specificity of 0.79 (0.54–0.94) and AUC of 0.79 (0.64–0.95), respectively. <h3>Conclusion</h3> This pilot study offers the potential for early non-invasive tracking of liver disease using urinary VOC bio-odorant fingerprints to distinguish patients with a disease within the spectrum of fatty liver disease from healthy controls, but also to distinguish subsets of the spectrum from each other, such as NASH from NAFLD. This may develop into a viable alternative surveillance or diagnostic tool in patients unable or unwilling to undergo liver biopsy. <h3>Disclosure of interest</h3> None Declared.
Cachexia in Radiotherapy-Treated Patients With Head and Neck Cancer—Reply
Authors: Aaron J. Grossberg, Abdallah S. R. Mohamed, Clifton David Fuller
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
CD4+ T cell–independent DNA vaccination against opportunistic infections
Authors: Mingquan Zheng, Alistair J. Ramsay, Myles B. Robichaux, Corrine Kliment, Christopher Crowe, Rekha R. Rapaka, Chad Steele, Florencia McAllister, Judd E. Shellito, Luis Marrero, Paul Schwarzenberger, Qiu Zhong, Jay K. Kolls
Journal: Journal of Clinical Investigation (2015)

Original citation: J Clin Invest. 2005;115(12):3536–3544. doi:10.1172/JCI26306.

Citation for this corrigendum: J Clin Invest. 2015;125(3):1364. doi:10.1172/JCI81228.

Karen A. Norris has requested to be removed from the author list, and the corresponding author has agreed. The revised author list is shown above.
Extension of Cellophane Substrate Procedure to Growth of &lt;italic&gt;in vitro&lt;/italic&gt; Cultures of Large Areas
Authors: Wilton R. Earle, Virginia J. Evans, Edward L. Schilling
Journal: JNCI Journal of the National Cancer Institute (1950)

Extension of Cellophane Substrate Procedure to Growth of in vitro Cultures of Large Areas Get access Wilton R. Earle, Wilton R. Earle Search for other works by this author on: Oxford Academic PubMed Google Scholar Virginia J. Evans, Virginia J. Evans Search for other works by this author on: Oxford Academic PubMed Google Scholar Edward L. Schilling Edward L. Schilling National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 4, February 1950, Pages 943–967, https://doi.org/10.1093/jnci/10.4.943 Published: 01 February 1950 Article history Received: 13 December 1949 Published: 01 February 1950
AB0649 Serum GDF-15 Level in Behçet's Disease: Relationship Between the Disease Activity and Clinical Parameters
Authors: M.A. Sarıyıldız, L. Yazmalar, I. Batmaz, M. Alpaycı, Y.K. Burkan, B. Sula, I. Kaplan, M. Yıldız, Z.A. Akar, M. Bozkurt
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Growth differentiation factor (GDF)-15, a member of the transforming growth factor-β superfamily of cytokines, plays an important role in cell growth, signal transduction, and apoptosis regulation. <h3>Objectives</h3> The aim of this study was to evaluate serum GDF-15 levels and their relationship with disease-related variables in patients with Behçet9s disease (BD). <h3>Methods</h3> Forty-six patients diagnosed with BD and 30 demographically matched healthy control subjects participated in the study. GDF-15 levels were measured in blood samples from patients and controls. Behçet9s Disease Current Activity Form (BDCAF) was used to evaluate the disease activity of BD. <h3>Results</h3> There were no significant differences between the two groups in regard to C-reactive protein (CRP), mean erythrocyte sedimentation rate, age, body mass index and mean GDF-15 levels (p&gt;0.05). The serum GDF-15 levels were positively correlated with peripheral arthritis, CRP, BDCAF erythema nodosum, BDCAF arthralgia, and BDCAF arthritis scores. The patients with BD were divided into twogroups according to the presence of peripheral arthritis; nine subjects (20%) were positive for peripheral arthritis. Serum ESR, CRP, white blood cell, and GDF-15 levels were significantly higher in the group that was positive for peripheral arthritis (p&lt;0.05). <h3>Conclusions</h3> GDF-15 may play a role in the progression and pathway of Behçet9s joint involvement and erythema nodosum independent of classic inflammatory response measures. <h3>References</h3> Wong RC, Ellis CN, Diaz LA et al Behcet9s disease. Int J Dermatol 1984; 23: 25–32. Takeuchi M, Keino H, Suzuki J et al. Possibility of inducing anterior chamber-associated immune deviation by TGF-beta 2 treatment of monocytes isolated from Behcet9s patients. Exp eye res 2006; 83: 981–988 Yazmalar L, Batmaz I, Sarıyıldız MA et al. Sleep quality in patients with Behçet9s disease. Int J Rheum Dis 2014; doi: 10.1111/1756-185X.12459. Canete JD, Celis R, Noordenbos T et al. Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis res ther 2009; 11: R17 <h3>Disclosure of Interest</h3> None declared
Myositis in Guinea Pigs&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: Leon Z. Saunders, DVM
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Myositis in Guinea Pigs Get access Leon Z. Saunders, DVM Leon Z. Saunders, DVM Brookhaven National Laboratory, Upton, Long Island, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 5, May 1958, Pages 899–903, https://doi.org/10.1093/jnci/20.5.899 Published: 01 May 1958
Changing a state mental health system through litigation: the Arizona experiment
Authors: J M Santiago, A Gittler, A Beigel, L Stein, P J Brown
Journal: American Journal of Psychiatry (1986)

Litigation may be a viable means to change mental health systems for the chronically mentally ill. Court orders achieved in the 1970s have been ignored or proven inefficient over the years. However, in Arizona, a strategy was designed by a team of lawyers and psychiatrists to deal with failures seen elsewhere in court actions seeking adequate services for chronically mentally ill patients. This novel approach produced a favorable court outcome and triggered a chain reaction at the executive and legislative levels to reform radically the system of care for the chronically mentally ill in Arizona.
Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis
Authors: F. Gómez-García, D. Epstein, B. Isla-Tejera, A. Lorente, A. Vélez García-Nieto, J. Ruano
Journal: British Journal of Dermatology (2016)

A new generation of biologics targeting the interleukin-23-T helper 17 pathway has been developed. This study aimed to assess the short-term effectiveness and safety of these new agents using a network meta-analysis. Twenty-seven randomized clinical trials (10 629 patients) were identified by a comprehensive systematic literature review (PROSPERO 2015: CRD42015025472). Quality of evidence was assessed following Cochrane-compliant rules and the Grading of Recommendations, Assessment, Development and Evaluations approach. Efficacy and safety outcomes at weeks 10-16 were compared using a random-effects network meta-analysis within a frequentist framework to estimate pooled odds ratios (ORs) of direct and indirect comparisons among the therapeutic options. There were six direct drug-to-drug comparisons in the network, with a high degree of consistency between the direct and indirect evidence. From the available evidence, infliximab 5 mg kg-1 every 8 weeks [OR 118·89, 95% confidence interval (CI) 60·91-232·04] and secukinumab 300 mg every 4 weeks (OR 87·07, 95% CI 55·01-137·82) are shown to be among the most effective short-term treatments, but are ranked as the biologics most likely to produce any adverse event or an infectious adverse event, respectively. Ustekinumab 90 mg every 12 weeks, the third most efficacious treatment (OR 73·67, 95% CI 46·97-115·56), was the only agent that did not show increased risk of adverse events compared with placebo. Treatment recommendations should also consider long-term outcomes and costs.
Therapeutic effect of sleep deprivation in patients with premenstrual syndrome
Authors: B L Parry, T A Wehr
Journal: American Journal of Psychiatry (1987)

Eight of 10 women with premenstrual depression responded to one night's total sleep deprivation and maintained their improvement after a night of recovery sleep. In responders, subsequent late-night partial sleep deprivation was more effective than early-night deprivation.